Sequential Antibiotic Therapy: Effective Cost Management and Patient Care
Author(s) -
Lionel A. Mandell,
Michel G. Bergeron,
Marie J. Gribble,
Peter J. Jewesson,
Donald E. Low,
Thomas J. Marrie,
Lindsay E. Nicolle
Publication year - 1995
Publication title -
canadian journal of infectious diseases and medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1918-1493
pISSN - 1712-9532
DOI - 10.1155/1995/165848
Subject(s) - medicine , intensive care medicine , changeover , drug , health care , pharmacology , electrical engineering , transmission (telecommunications) , engineering , economics , economic growth
The escalating costs associated with antimicrobial chemotherapy have become of increasing concern to physicians, pharmacists and patients alike. A number of strategies have been developed to address this problem. This article focuses specifically on sequential antibiotic therapy (sat), which is the strategy of converting patients from intravenous to oral medication regardless of whether the same or a different class of drug is used. Advantages of sat include economic benefits, patient benefits and benefits to the health care provider. Potential disadvantages are cost to the consumer and the risk of therapeutic failure. A critical review of the published literature shows that evidence from randomized controlled trials supports the role of sat. However, it is also clear that further studies are necessary to determine the optimal time for intravenous to oral changeover and to identify the variables that may interfere with the use of oral drugs. Procedures necessary for the implementation of a sat program in the hospital setting are also discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom